Experience with terlipressin (TP) in the neonatal field is scarce. We describe the effects of TP on pulmonary circulation, studied with echocardiography, in an asphyxiated septic cooled infant with pulmonary hypertension (PH) who developed catecholamine-resistant hypotension and exacerbation of PH shortly after the beginning of the rewarming. TP was added to norephinephine and adrenaline infusions at the dose of 0.02 mg kg À1 every 6 h, because of refractory hypotension and oliguria. After 10 min, blood pressure dramatically and definitely increased, and urinary output was re-established after 60 min. Echocardiographic evaluation 30 min after the second bolus of TP showed unchanged velocity of the tricuspidal valve regurgitation and improved biventricular functional indexes respect to the pre-treatment assessment. TP was continued for 12 h (three doses) without significant adverse effect except for a transient increase in troponin levels. Addition of TP boluses to catecholamine infusion in our newborn was effective in increasing systemic vascular resistance without increasing pulmonary vascular resistance, successfully reversing the hemodynamics of severe PH, and suggesting a potential primary vasodilator effect on pulmonary circulation. Transient increase of troponin levels during TP treatment confirms the risk of excessive coronary vasoconstriction when TP boluses are added to high dose catecholamines.
Introduction
Mild whole-body hypothermia does not cause hazardous hemodynamic changes in the systemic or pulmonary circulation. However, neonatal sepsis and perinatal asphyxia may impair thermoregulatory vasoconstriction in cooled infants, leading to extreme cardiovascular instability especially during the rewarming phase. Terlipressin (TP) is a synthetic analog of arginine vasopressin (AVP) successfully used to treat hypotension from several causes. 1, 2 In newborn infants, experience with TP use is scarce and mainly limited to the treatment of refractory hypotension of septic origin; [3] [4] [5] [6] however, TP has also been used as a rescue therapy for refractory pulmonary hypertension (PH) associated with congenital diaphragmatic hernia 3, 7, 8 and therapeutic hypothermia, 3 suggesting a possible vasodilatory effect of TP on pulmonary circulation. We describe our experience with TP in an asphyxiated septic newborn with moderate PH at birth treated with mild whole-body hypothermia, who developed catecholamine-resistant hypotension and exacerbation of PH during passive rewarming.
Case
A 3880-g male infant was born at 40 weeks of gestational age by emergency cesarean delivery because of perinatal asphyxia. At birth, resuscitation was required; Apgar scores were 4 and 7 at 1 0 and 5 0 , respectively. Initial laboratory findings revealed high C-reactive protein levels (215 mg dl À1 , normal: <8 mg dl À1 ) and increased liver and myocardic enzymes (ALT 156 UI ml À1 , normal: <45 UI ml À1 ; AST 381 UI ml À1 , normal: <45 UI ml À1 ; troponin 0.48 ng ml À1 , normal: <0.04 ng ml À1 ). An echocardiographic evaluation showed mild PH with tricuspid valve regurgitation (peak velocity 3.0 m s À1 ) with an estimated pulmonary pressure of 41 mm Hg vs a systolic blood pressure of 87 mm Hg. The electroencephalogram showed burst suppression. Antibiotic therapy, inhaled nitric oxide at 20 p.p.m. and mild systemic hypothermia were instituted. Shortly after therapeutic cooling initiation, the baby developed tachycardia and hypotension that was treated with volume expansion and dopamine. Hypotension was difficult to control despite increasing doses of dopamine, and worsened on the third day (41/17 mm Hg, MAP 32 mm Hg). Dopamine was replaced with noradrenaline and adrenaline infusions at 0.5 and 1 mg kg À1 per min, respectively. An echocardiographic assessment at this time point (immediately before the beginning of the rewarming phase) revealed increased tricuspid valve regurgitation (peak velocity of 4.6 m s À1 ), with an estimated pulmonary artery pressure at suprasystemic levels (PAP>85 mm Hg vs SBP ¼ 80 mm Hg). Left and right ventricular output (256 and 430 ml kg À1 per min, respectively) and superior vein cava flow (55 ml kg À1 per min) were adequate, whereas both left and right myocardial performance index were similar and slightly increased (0.51). Because of the maximal oxygen requirements (FiO 2 ¼ 1), rescue high frequency oscillatory ventilation was initiated and inhaled nitric oxide augmented to 35 p.p.m. Shortly after the rewarming was started, the baby again presented hypotension (51/23 mm Hg, MAP 30 mm Hg) and reduction in the urine output (0.7 ml kg À1 per h), unresponsive to volume loads and furosemide boluses. After a written informed parental consent was obtained, TP was started at the dose of 0.02 mg kg À1 every 6 h. After 10 min, blood pressure increased dramatically (116/66 mm Hg, MAP 79 mm Hg) and kept stable thereafter. Diuresis was re-established and doubled after 60 min. Oxygen requirements remained high (FiO 2 ¼ 0.9) but oxygen saturation become adequate and stable. Treatment with TP was continued for 12 h (3 doses). Noradrenaline and adrenaline infusions were stopped 1 and 3 days after the first dose of TP, respectively. Echocardiographic assessment performed 30 min after the second bolus of TP showed unchanged tricuspid valve regurgitation (peak velocity of 4.5 m s À1 ), a significant increase of both left and right ventricular output (465 and 688 ml kg À1 per min, respectively), and of superior vein cava flow (80 ml kg À1 per min), with a concurrent decrease of both left and right myocardial performance index (0.24 and 0.27, respectively). Thereafter, clinical conditions progressively improved and the patient was weaned off inhaled nitric oxide and oxygen after 1 week. Echocardiographic assessment at discharge (34 days of life) showed good biventricular function and complete disappearance of signs of increased PAP. No adverse effects were observed following TP use except for a transient rise of AST (from 68 to 103 UI ml À1 ), ALT (from 21 to 68 UI ml À1 ) and troponin (from 1.04 to 2.27 ng ml À1 ) above pre-treatment levels.
Discussion TP is a synthetic analog of AVP with greater selectivity for the V1 receptor, but a significantly longer half-life, allowing for intermittent administration without hypotension rebound at drug withdrawal. 9 Both AVP and TP have been proven effective in treating sepsis-related hypotension and reducing catecholamine requirements in the experimental 10, 11 and clinical 12, 13 settings. While TP may hold theoretical and anecdotal advantages over AVP, this has not been formally tested in prospective randomized trials, and its use remains controversial.
14 Of particular interest is whether TP exerts a vasodilatory effect on the pulmonary bed as AVP reportedly may do. 15, 16 Stathopoulos et al. 8 presented a case report of a neonate with congenital diaphragmatic hernia and hypoxemic respiratory failure, where TP infusion reduced PH and improved systemic blood pressure. Other cases supporting the hypothesis that TP may decrease pulmonary vascular resistance have also been published. 3, 7 However, the reported effects of TP on pulmonary circulation seem conflicting and mainly in the context of portopulmonary hypertension. 17 Our patient had multiorgan system failure secondary to asphyxia and sepsis with severe hypotension and PH unresponsive to inhaled NO. The echocardiographic evaluation performed after the second bolus of TP showed a 60% increase in right ventricular output but no change of the tricuspidal valve regurgitation peak velocity, which is known to be the most sensitive and repeatable echocardiographic index of pulmonary arterial pressure in the newborn. 18 Assuming no vast changes in atrial pressure, and approximating mean PAP by known formulas, 19 this fact alone accounts for a reduction of pulmonary vascular resistance of about 40%. According to Matok et al., 6 we also found a significant improvement in cardiac performance after TP administration, although intermittent bolus administration of TP is believed to be potentially associated with decreased cardiac output. In particular, we found significant decrease of both left and right ventricles myocardial performance index, a Doppler-derived nongeometric and non-volumetric index, highly advantageous in assessing global cardiac function, expressly in presence of distorted right ventricle shape because of severe PH. 20 TP treatment was well tolerated; however, the simultaneous transient further increase of troponin levels observed during TP treatment confirms the potential risk of excessive coronary vasoconstriction, suggesting that continuous low-dose infusion should be preferred in presence of high doses of catecholamine infusion.
Conclusion
Notwithstanding the very limited experience of TP use in cooled infants, 3 our report suggests that this vasopressor may be useful in complex circulatory disturbances, such as the one we describe, reversing the shock state and improving pulmonary blood flow, possibly through a reduction of pulmonary vascular resistance. TP seems to not affect negatively cardiac function, but low-dose continuous infusion should be preferred to avoid excessive coronary vasoconstriction when added to high doses of catecholamines infusion. Additional studies are necessary to define the safety profile and the clinical effectiveness of TP in neonates.
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